Anti-obesity Drugs Market in the US 2015-2019 with Arena, F. Hoffmann-La Roche, GSK, Novo Nordisk, Orexigen Therapeutics & Vivus Dominating
DUBLIN, Aug. 31, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/lvk9jp/antiobesity) has announced the addition of the "Anti-obesity Drugs Market in the US 2015-2019" report to their offering.
The anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019.
The report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Many anti-obesity drugs have been issued complete response letters (CRLs) by the FDA before approval. For instance, the FDA issued a CRL to Takeda/Orexigen Therapeutics's Contrave in 2010, which requested further details regarding the cardiovascular safety profile of the drug when used over the long term in a population of overweight and obese subjects. Similarly, Vivus/Eisai's Qsymia was also issued a CRL, which requested further details regarding the clinical label, Risk Evaluation and Mitigation Strategy, safety update, and drug scheduling data. Thus, stringent regulations will hamper market growth.
According to the report, Epidemiological statistics clearly signify that the target population for anti-obseity drugs is huge. In addition, advances in medical technologies have led to a rise in the number of people diagnosed with obesity. Thus the high number of overweight people coupled with improved diagnostics will drive the growth of the market.
Further, the report states that enormous R&D expenses coupled with high attrition rates pose a major challenge to the discovery and development of anti-obesity drugs.
Key Vendors
- Arena Pharmaceuticals
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Novo Nordisk
- Orexigen Therapeutics
- Vivus
Other Prominent Vendors
- Alizyme
- Amylin
- Boehringer Ingelheim
- Eisai
- Merck
- Norgine
- Pfizer
- Rhythm Pharmaceuticals
- Shionogi USA
- Takeda Pharmaceutical
- Zafgan
Key Topics Covered:
- Executive Summary
- List of Abbreviations
- Scope of the Report
- Product Profiles
- Market Research Methodology
- Introduction
- Disease Overview
- Market Landscape
- Market Segmentation by Drug Class
- Market Segmentation by Medication Type
- Buying Criteria
- Market Growth Drivers
- Drivers and Their Impact
- Market Challenges
- Impact of Drivers and Challenges
- Market Trends
- Trends and Their Impact
- Vendor Landscape
- Key Vendor Analysis
For more information visit http://www.researchandmarkets.com/research/lvk9jp/antiobesity
Media Contact:
Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article